证券代码：688139 证券简称：海尔生物 公告编号：2025-022 青岛海尔生物医疗股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示 现金管理金额：不超过人民币 270,000 万元，在上述额度范围内，资金 可以滚动使用； 现金管理产品类型：安全性高、流动性好、产品发行主体能够提供保本 承诺的投资产品。投资产品不得用于质押，不得用于以证券投资为目的的投资行 为； 现金管理期限：自公司董事会审议通过之日起 12 个月内； 履行的审议程序：公司第三届董事会第五次会议及第三届监事会第四次 会议分别审议通过了《关于使用闲置自有资金进行现金管理的议案》，同意公司 使用闲置自有资金进行现金管理。 一、公司拟使用部分暂时闲置自有资金进行现金管理的情况 （一）现金管理的目的 1 为提高公司资金使用效率，增加股东回报，在确保不影响公司正常经营，并 保证资金流动性、安全性，并有效控制风险的前提下，公司拟使用部分暂时闲置 的自有资金进行现金管理，以增加资金收益、保持资金流动 ...

青岛海尔生物医疗股份有限公司 募集资金存放与实际使用情况鉴证报告 2024年12月31日 青岛海尔生物医疗股份有限公司 目 录 募集资金存放与实际使用情况鉴证报告 | 一、募集资金存放与实际使用情况鉴证报告 | 1 | | --- | --- | | 二、青岛海尔生物医疗股份有限公司募集资金存放与实际使用情况的专项报告 | 2 - 8 | 页次 安永华明（2025）专字第70033365_J02号 青岛海尔生物医疗股份有限公司 青岛海尔生物医疗股份有限公司董事会： 我们接受委托，对后附的青岛海尔生物医疗股份有限公司2024年度募集资金存放与实际 使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监管指引第2号— —上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创板上市公司自律监管指 引第1号——规范运作》及相关格式指南编制募集资金专项报告，并保证其内容真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏是青岛海尔生物医疗股份有限公司董事会的责任。 我们的责任是在执行鉴证工作的基础上对募集资金专项报告独立发表鉴证意见。 我们按照《中国注册会计师其他鉴证业务准则第3101号——历 ...

重要内容提示 本日常关联交易预计事项需提交股东大会审议。青岛海尔生物医疗股份 有限公司（以下简称"公司"或"海尔生物"）2025 年与关联方拟进行一系列 日常关联交易，总金额不超过 28,523.62 万元。其中采购类（包括原材料、商品、 能源、服务等）关联交易预计全年发生额为 14,631.32 万元；销售类（主要为销 售产品、服务等）关联交易预计全年发生额为 13,892.30 万元。 日常关联交易定价政策和定价依据遵照公开、公平、公正的原则，按照 市场价格结算，不会对公司及公司财务状况、经营成果产生不利影响，不存在损 害公司及全体股东特别是中小股东利益的行为，公司主营业务不会因上述交易而 对关联方形成依赖，不会影响公司的独立性。 1 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 证券代码：688139 证券简称：海尔生物 公告编号：2025-023 青岛海尔生物医疗股份有限公司 关于预计 2025 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 青岛海尔生物医疗股份有限公司（以 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-024 重要内容提示： 拟聘任的会计师事务所名称 安永华明会计师事务所（特殊普通合伙） 青岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）于 2025 年 3 月 28 日召开第三届董事会第五次会议，审议通过了《关于续聘会计师事务 所的议案》，公司拟继续聘请安永华明会计师事务所（特殊普通合伙）（以下简称 "安永华明"）为公司 2025 年度财务报告及内部控制审计机构。现将有关情况公 告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 安永华明于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合 作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 青岛海尔生物医疗股份有限公司 （二）项目信息 1.基本信息 签字项目合伙人： ...

Financial Performance - The company's operating revenue for 2024 reached CNY 2,283,832,911.43, showing a slight increase of 0.13% compared to 2023 [24]. - The net profit attributable to shareholders for 2024 was CNY 366,632,797.05, a decrease of 9.71% year-over-year, primarily due to non-operating factors [26]. - Basic earnings per share for 2024 were CNY 1.16, down 9.38% from CNY 1.28 in 2023 [25]. - The company's total assets as of the end of 2024 were CNY 5,787,468,795.01, reflecting a 4.74% increase from the previous year [24]. - The gross margin for 2024 was 47.99%, with a restated gross margin of 50.43% when accounting for new accounting policies [40]. - The company's operating revenue for 2024 reached CNY 2,283.83 million, a slight increase of 0.13% compared to the previous year [133]. - Operating costs increased to CNY 1,187.91 million, reflecting a rise of 1.33% year-on-year [133]. - The net cash flow from operating activities improved by 17.01%, totaling CNY 291.67 million compared to CNY 249.26 million in the previous year [134]. Research and Development - Research and development expenses accounted for 13.41% of operating revenue in 2024, a slight decrease from 14.06% in 2023 [25]. - The total R&D investment for the year was approximately ¥306.17 million, a decrease of 4.51% compared to the previous year, with the R&D investment as a percentage of operating income decreasing by 0.65 percentage points to 13.41% [106]. - R&D expenses have consistently remained above 10% of total revenue, indicating a strong commitment to innovation and development [118]. - The company achieved a 21% year-on-year increase in patent authorizations, with a 66% increase in invention patent authorizations during the reporting period [117]. - The company has accumulated a total of 1,595 patents and has developed six major technology platforms, maintaining a leading position in biomedicine and medical innovation [60]. Corporate Governance - The company has confirmed that all board members attended the board meeting [6]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report [12]. - The company has not violated any decision-making procedures in providing guarantees [11]. - The company has established specialized committees, including audit, nomination, compensation, and strategic committees, with specific members assigned to each [199]. - The company has implemented strict procedures for related party transactions to protect the interests of minority shareholders [175]. Market Expansion and Strategy - The company plans to accelerate its overseas market expansion, anticipating significant growth in 2025 [138]. - The company is focusing on the integration of IoT, cloud computing, and AI in the life sciences and medical innovation sectors, enhancing user value through digital scene solutions [120]. - The company is actively managing industry policy risks and enhancing its operational management to adapt to potential regulatory changes in the medical device sector [129]. - The company is transitioning from a "one-time product transaction" model to a "continuous value-added service" model, aiming to create lifelong value for users [120]. - The company is exploring strategic acquisitions to bolster its technology portfolio, with a budget of $200 million allocated for potential deals in 2024 [186]. Product Development and Innovation - The company launched several innovative products, including the "Life Ark" series and "Wuji" series, enhancing its smart laboratory solutions [43]. - The company has launched five new product categories, including an automated liquid nitrogen storage system and a temperature-controlled medical refrigerator, with 32 achievements recognized as internationally leading [50]. - The company has developed a digital public health platform, "Immunity Cloud," leveraging its vaccine city network, enhancing its competitive edge in public health information technology [57]. - The company has introduced new technologies such as laser coding for cryopreservation tubes, supporting full lifecycle traceability and obtaining CE certification rapidly [58]. - The company has launched an AI vaccine management system and 3D-AI visual recognition self-learning technology, supporting rapid development in automation [95]. Financial Management - The company reported a significant decline in investment cash flow, with a net outflow of CNY 791.22 million, compared to a net inflow of CNY 252.76 million last year, marking a 413.04% change [134]. - The company's overseas sales accounted for 31.43% of total revenue, a decrease of 3.04 percentage points from the previous year [138]. - The company invested CNY 20,380.76 million during the reporting period, a decrease of 42.26% compared to CNY 35,300 million in the same period last year [155]. - The company’s inventory increased by 34.97% to CNY 334,744,974.95 due to undelivered projects [151]. - The company’s short-term borrowings increased by 66.64% to CNY 10,009,027.78 from CNY 6,006,328.77 in the previous period [151]. Shareholder Engagement - The company held 2 shareholder meetings during the reporting period, ensuring compliance with regulations and allowing all shareholders, especially minority shareholders, to exercise their rights [174]. - The company engaged with institutional investors over 110 times and conducted 4 earnings briefing sessions during the reporting period [177]. - The company has established a multi-channel communication mechanism with investors, including a dedicated investor relations section on its official WeChat account [177]. - The company has not faced significant differences in governance compared to regulations set by the China Securities Regulatory Commission [178]. - The company confirmed its independence from the controlling shareholder in terms of operations and decision-making processes [179].

中证互联网医疗主题指数下跌0.62%，前十大权重 包含海尔生物等 从中证互联网医疗主题指数持仓样本的行业来看，医药卫生占比68.25%、信息技术占比27.60%、通信 服务占比4.14%。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将 其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 金融界3月26日消息，上证指数低开震荡，中证互联网医疗主题指数 (CS互医疗，930720)下跌0.62%， 报2648.49点，成交额56.65亿元。 跟踪CS互医疗的公募基金包括：汇添富中证互联网医疗A、汇添富中证互联网医疗C。 数据统计显示，中证互联网医疗主题指数近一个月下跌4.10%，近三个月上涨9.38%，年至今上涨 12.70%。 来源：金融界 据了解，中证互联网医疗主题指数选取为医疗信息化、智能化提供硬件、软件或服务的代表性公司作为 样本，以反映互 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-015 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 | 回购方案首次披露日 | 2025/1/14 | | --- | --- | | 回购方案实施期限 | 第三届董事会第四次会议审议通过后 12 个月 | | 预计回购金额 | 10,000 万元~20,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 323,614 股 | | 累计已回购股数占总股本比例 | 0.1018% | | 累计已回购金额 | 10,561,505.18 元 | | 实际回购价格区间 | 31.78 元/股~33.80 元/股 | 一、 回购股份的基本情况 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 1 月 13 日召 开第三届董事会第四次会议，审议通 ...

Financial Performance - Total revenue for 2024 reached RMB 2,283.83 million, a slight increase of 0.13% compared to RMB 2,280.90 million in the previous year[3] - Operating profit decreased by 8.34% to RMB 401.83 million from RMB 438.40 million year-on-year[3] - Net profit attributable to shareholders of the parent company was RMB 366.63 million, down 9.71% from RMB 406.07 million in the previous year[3] - Basic earnings per share decreased by 9.38% to RMB 1.16 from RMB 1.28 year-on-year[3] Asset and Cash Flow - Total assets increased by 4.74% to RMB 5,787.47 million from RMB 5,525.68 million at the beginning of the period[4] - The company achieved a 17.01% year-on-year increase in net cash flow from operating activities, supporting long-term healthy development[7] Market Growth and Strategy - Fourth-quarter revenue growth accelerated to 10.40%, with all markets and sectors showing positive growth[5] - Non-storage new industries maintained a growth rate of over 20% throughout the year, driven by continuous product innovation[5] - The company aims to enhance overseas localization and AI-driven digital upgrades to return to normal growth trajectories[7] Financial Reporting - The financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[9]

证券代码：688139 证券简称：海尔生物 公告编号：2025-013 青岛海尔生物医疗股份有限公司 关于实际控制人的一致行动人增持公司股份 达到 1%的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 本次权益变动属于增持，不触及要约收购。 本次权益变动后，青岛海创智管理咨询企业（有限合伙）持有公司股份 6,706,559 股，占公司总股本的 2.11%。海尔集团公司通过其控制的青岛海尔生 物医疗控股有限公司（以下简称"海尔生物医疗控股"）和青岛海创睿股权投资 基金中心（有限合伙）（以下简称"海创睿"）分别持有公司股份 100,591,463 股和 32,103,659 股，分别占公司总股本的 31.64%和 10.10%。海尔集团公司及其 一致行动人合计持有公司股份 139,401,681 股，占公司总股本的 43.84%。 本次权益变动不会使公司控股股东、实际控制人发生变化。 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 2 月 25 日 收到公司实际控制人海 ...

Group 1 - Haier Biomedical executed three block trades on February 20, totaling 615,700 shares and a transaction amount of 19.5766 million yuan [1] - The transaction price was 31.80 yuan, reflecting a discount of 5.94% compared to the closing price on the same day [1] - Institutional special seats participated in two of the trades, with a total transaction amount of 14.33 million yuan and a net purchase of 14.33 million yuan [1] Group 2 - Over the past three months, Haier Biomedical has recorded a total of 22 block trades, amounting to 221 million yuan [1]